This new research, published in the Genes & Diseases journal by a team from the South China University of Technology School of Medicine, investigated the mechanistic role of the chloride channel accessory 4 (CLCA4) in governing CRC stemness and its potential to sensitize tumors to immunotherapy.

Clinical cohort analyses and extensive in vitro experiments revealed that CLCA4 expression is significantly downregulated in chemoresistant CRC cells and CD133⁺/CD44⁺ colorectal CSCs, with this deficiency strongly correlating with advanced tumor progression and poor patient survival. By establishing stable CLCA4-overexpressing CRC cell lines, researchers demonstrated a dramatic reduction in tumorsphere formation, cell motility, and the expression of core stemness genes such as Bmi-1 and Oct4.

Mass spectrometry and immunoprecipitation analyses identified the underlying molecular mechanism, revealing that CLCA4 directly interacts with vimentin to promote its degradation, which subsequently inactivates the FAK signaling pathway. This targeted suppression of the vimentin-FAK axis critically halts CSC self-renewal and expansion. Conversely, restoring vimentin or activating FAK successfully reversed the tumor-suppressive effects of CLCA4, confirming this highly specific signaling network.

Remarkably, in vivo mouse xenograft and liver metastasis models confirmed that elevating CLCA4 expression not only impaired tumor growth but also profoundly reshaped the tumor immune microenvironment, sensitizing CRC to anti-PD-1 immunotherapy. CLCA4 overexpression triggered the secretion of the chemokine CXCL10, leading to a massive infiltration of cytotoxic CD8⁺ T cells and transforming the tumors from an immunosuppressive to an immunostimulatory state. Consequently, the combination of CLCA4 overexpression and anti-PD-1 therapy significantly reduced both primary tumor volume and hepatic metastatic lesions compared to monotherapy alone.

While these collective data robustly highlight the vital role of targeting CSC properties to overcome adaptive immune resistance, additional studies are necessary to translate these findings into clinical applications.

In conclusion, this study identifies CLCA4 as a dual-function regulator that suppresses CSC-driven tumor progression while simultaneously enhancing anti-tumor immunity. Targeting the CLCA4 signaling axis may offer a promising therapeutic strategy to overcome resistance and improve immunotherapy outcomes in colorectal cancer.

Reference
Title of Original Paper: Chloride channel accessory 4 suppresses stem cell-like properties of colorectal cancer and enhances anti-PD-1 immunotherapy

Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101859

Funding Information:

1. The National Natural Science Foundation of China (No. 81972780)
2. The Natural Science Foundation of Guangdong Province, China (No. 2020A1515010051)

# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4
Impact Factor: 9.4
# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #